Alion Pharmaceuticals and LamdaGen Corporation Announce Collaboration to Accelerate Small Molecule Drug Development

Rapid identification of compounds to treat neurodegenerative diseases

Menlo Park, California – Alion Pharmaceuticals and LamdaGen Corporation announced today that the two biotechnology companies have entered into a Strategic Collaboration to identify and characterize small molecule inhibitors for the treatment of neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s Disease, and Neuropathic Pain.

The Collaboration combines Alion’s proprietary computer aided drug design technology and methodologies with LamdaGen’s highly sensitive nano-sensor based bioanalytical systems to accelerate the identification of novel small molecule drug candidates to treat neurologic disorders.

“Recent efforts between our two organizations have led to the validated activity of several Alion compounds directed against targets of therapeutic value in Alzheimer’s disease. With combined use of our respective technologies, we have demonstrated that protein/peptide interactions can be regulated with our small molecule inhibitors. This has important implications for the identification of new therapeutic drugs, which makes this early stage discovery and validation activity very exciting,” stated Allan Bates, President of Alion.

The companies are in discussion with several pharmaceutical companies regarding the utilization of their integrated discovery technologies for use in specific drug discovery and development programs.

About Alion: Alion Pharmaceuticals is a computational chemistry company employing proprietary CADD and biophysical methodologies to accelerate the discovery and development of small molecule therapeutics.

About LamdaGen: LamdaGen Corporation is a rapidly growing biosensor company utilizing proprietary nano-based metamaterials to facilitate improved testing and analyses for drug discovery and development, as well as diagnostic applications.

For more information: